Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia

IMPORTANCE: The most prescribed class of medications for benign prostatic hyperplasia (BPH) is α-blockers (ABs). However, the cardiovascular safety profile of these medications among patients with BPH is not well understood. OBJECTIVE: To compare the safety of ABs vs 5-α reductase inhibitors (5-ARIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jiandong, Latour, Chase D., Olawore, Oluwasolape, Pate, Virginia, Friedlander, David F., Stürmer, Til, Jonsson Funk, Michele, Jensen, Brian C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646730/
https://www.ncbi.nlm.nih.gov/pubmed/37962887
http://dx.doi.org/10.1001/jamanetworkopen.2023.43299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646730/
https://www.ncbi.nlm.nih.gov/pubmed/37962887
http://dx.doi.org/10.1001/jamanetworkopen.2023.43299

Ejemplares similares